Overview of HIV treatment failure in Africa using the WHO Pharmacovigilance data.
OBJECTIVE: To characterise the factors associated with HIV treatment failure (HIVTF) from reported pharmacovigilance data in Africa.
MATERIALS AND METHODS: This is an observational pharmacovigilance analysis of the safety data of HIVTF available in the WHO International Pharmacovigilance database 'VigiBase((R)) '. We used the Standardised MedDRA Queries (SMQ) to identify all the terms corresponding to HIVTF. To identify all relevant molecules and classes of antiretroviral therapy, we used the anatomic, therapeutic, and chemical classification. We presented results as a percentage or an adjusted Reporting Odds Ratio (aROR) with a 95% confidence interval (95% CI).
RESULTS: HIVTF was more reported in Africa compared with the rest of the world with 19.1% (18.1%-20.1%) corresponding to 1206 of all 6304 HIVTF reports. Among all the 37 WHO country members in Africa, South Africa was the main source of origin for these HIVTF reports with 86.8% (84.9%-88.7%). Compared to adults, children and adolescents were the most population groups affected by HIVTF, aROR = 2.7, (95% CI) 1.7-4.2 and aROR = 7.9, (95% CI) 4.5-13.9, respectively.
CONCLUSION: South Africa was the leading country of the reporting of HIVTF in Africa. The proportion of HIVTF was higher in both HIV-infected children and adolescents than in adults. There is a need for the improvement of medical care for children and adolescents with HIV infection in Africa.
|ジャーナル名||Tropical medicine & international health : TM & IH|
|投稿者||Miantezila Basilua, Joe; Mesia Kahunu, Gauthier; Pochart, Philippe; Tona Lutete, Gaston|
|組織名||Faculte de Medecine et de Pharmacie, Universite de Poitiers, Poitiers, France.;Centre National de Pharmacovigilance, Kinshasa, Democratic Republic of the Congo.;Microbial Ecology Laboratory, CNAM, Paris, France.|